Lewes, DE -- (SBWIRE) -- 09/12/2013 -- LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: Repsol SA (ADR)(OTCMKTS:REPYY), Allianz SE (ADR)(OTCMKTS:AZSEY), Cannabis Science Inc(OTCMKTS:CBIS), Koninklijke KPN N.V. (ADR)(OTCMKTS:KKPNY).
Repsol SA (ADR)(OTCMKTS:REPYY) ended higher +0.82% and complete the day at $24.60. The total number of shares changed hands during the day was 59,316. After opening at $24.49, the stock hit as high as $24.64. However, it traded between $18.62 and $24.64 over the last twelve months.
Repsol, S.A. operates as an integrated energy company engaging in upstream and downstream activities worldwide. The company is involved in the exploration, development, and production of crude oil and natural gas; transportation of oil products, liquefied petroleum gas (LPG), and natural gas;
For How Long REPYY will Fight for Profitability? Read This Trend Analysis report
Allianz SE (ADR)(OTCMKTS:AZSEY) closed yesterday at $15.10, a -0.32% decrease. Around 78,337 shares were traded, low from an-average trading volume of 224,537shares. The company is now valued at around $68.44 billion.
Allianz SE primarily provides property and casualty, and life/health insurance products to private and corporate customers worldwide. Its Property-Casualty Insurance segment offers various insurance products, including motor liability and own damage, accident, general liability, fire and property, legal expense, credit, and travel insurance products.
Has AZSEY Found The Bottom And Ready To Gain Momentum? Find Out Here
Cannabis Science Inc(OTCMKTS:CBIS) moved -2.66 percent lower at $0.0475 and traded between $0.05 and $0.05 after opening the day at $0.05. Its performance over the last five days remained 1.06%, which stands at 3.04% for a month. Going back further than one month, 1-year performance after recent close was -5%.
Cannabis Science, Inc., a development stage company, engages in the development, production, and commercialization of phytocannabinoid-based pharmaceutical products. It primarily focuses on developing medications to treat autism, blood pressure, cancer and cancer side effects, HIV, and other illnesses, including general health maintenance
Why Should Investors Buy CBIS After the Recent Fall? Just Go Here and Find Out
Koninklijke KPN N.V. (ADR)(OTCMKTS:KKPNY) shares rose, gaining +6.64 percent to close at $3.05. The stock is down around -38.76% this year and -64.37% for the last 12 months. Around 623,304 shares changed hands yesterday, higher from an-average trading volume of 168,327 shares.
Koninklijke KPN N.V., through its subsidiaries, provides telecommunications, and information and communication technology services. It offers fixed and mobile telephony, broadband Internet, and television service, as well as mobile access portfolio of voice, SMS, and data services offering postpaid and prepaid products to consumers.
Why Should Investors Buy KKPNY After The Recent Gain? Just Go Here and Find Out
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.
Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/